DE60239707D1 - Antimikrobielle kationische peptide und diese enthaltende formulierungen - Google Patents

Antimikrobielle kationische peptide und diese enthaltende formulierungen

Info

Publication number
DE60239707D1
DE60239707D1 DE60239707T DE60239707T DE60239707D1 DE 60239707 D1 DE60239707 D1 DE 60239707D1 DE 60239707 T DE60239707 T DE 60239707T DE 60239707 T DE60239707 T DE 60239707T DE 60239707 D1 DE60239707 D1 DE 60239707D1
Authority
DE
Germany
Prior art keywords
antimicrobial cationic
cationic peptides
formulations containing
infections
antimicrobial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239707T
Other languages
English (en)
Inventor
Timothy J Krieger
Patricia J Mcnicol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biowest Therapeutics Inc
Original Assignee
Migenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Migenix Inc filed Critical Migenix Inc
Application granted granted Critical
Publication of DE60239707D1 publication Critical patent/DE60239707D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE60239707T 2001-08-21 2002-08-21 Antimikrobielle kationische peptide und diese enthaltende formulierungen Expired - Lifetime DE60239707D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31423201P 2001-08-21 2001-08-21
US10/225,087 US6835536B2 (en) 2001-08-21 2002-08-20 Antimicrobial cationic peptides and formulations thereof
PCT/US2002/026525 WO2003015809A2 (en) 2001-08-21 2002-08-21 Antimicrobial cationic peptides and formulations thereof

Publications (1)

Publication Number Publication Date
DE60239707D1 true DE60239707D1 (de) 2011-05-19

Family

ID=26919289

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239707T Expired - Lifetime DE60239707D1 (de) 2001-08-21 2002-08-21 Antimikrobielle kationische peptide und diese enthaltende formulierungen

Country Status (8)

Country Link
US (5) US6835536B2 (de)
EP (1) EP1469876B1 (de)
JP (3) JP4932136B2 (de)
AT (1) ATE504308T1 (de)
AU (1) AU2002324752B2 (de)
CA (1) CA2456477C (de)
DE (1) DE60239707D1 (de)
WO (1) WO2003015809A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550558B2 (en) * 2001-06-01 2009-06-23 Fundacao De Ampara A Pesquiso Do Estado De Sao Paolo (Fapesp) Antimicrobial peptides and methods for identifying and using such peptides
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
WO2003018619A2 (en) * 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US20030144362A1 (en) * 2002-01-28 2003-07-31 Utterberg David S. High viscosity antibacterials for cannulae
US20060128614A1 (en) * 2002-09-20 2006-06-15 Jya-Wei Cheng Antimicrobial peptides with reduced hemolysis and methods of their use
BRPI0413521A (pt) 2003-08-14 2006-10-10 Diatos seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares
WO2005019241A2 (en) * 2003-08-18 2005-03-03 E.I. Dupont De Nemours And Company Cationic antimicrobial peptides and compositions thereof
ZA200602754B (en) * 2003-09-12 2007-06-27 Univ British Columbia Effectors of innate immunity determination
JP4736540B2 (ja) * 2004-05-27 2011-07-27 参天製薬株式会社 眼科用粘稠化剤
WO2005115475A1 (ja) * 2004-05-27 2005-12-08 Santen Pharmaceutical Co., Ltd. 眼科用粘稠化剤
WO2006050611A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
CN101300022A (zh) * 2005-08-01 2008-11-05 俄克拉荷马州大学评议会 抗真菌肽和其使用方法
US7790679B2 (en) * 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
WO2009025691A1 (en) * 2007-05-22 2009-02-26 New York University School Of Medicine Dendrimeric peptides, pharmaceutical compositions and methods of using the same
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
US20100055158A1 (en) * 2008-08-28 2010-03-04 Tyco Healthcare Group Lp Environmentally Activated Compositions, Articles and Methods
CA2779433A1 (en) * 2009-11-03 2011-05-12 Lipidor Ab Composition for promoting wound healing
US8916171B2 (en) 2010-04-27 2014-12-23 Topical Sinus Therapeutics, Inc. Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis
US8986399B2 (en) * 2011-05-25 2015-03-24 Empire Technology Development Llc Treating lignocellulosic materials
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
JP5894457B2 (ja) * 2012-02-22 2016-03-30 株式会社Adeka ペプチド含有抗菌性組成物
WO2013142374A1 (en) 2012-03-23 2013-09-26 Amirobe, Inc. Compositions and uses of antimicrobial materials with tissue-compatible properties
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA3004790A1 (en) 2015-11-10 2017-05-18 Visterra, Inc. Lipopolysaccharide binding antibody-antimicrobial peptide conjugates and uses thereof
EP3416669A1 (de) * 2016-02-19 2018-12-26 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Mittel und verfahren zur behandlung von bakteriellen infektionen
AU2018209940A1 (en) 2017-01-18 2019-07-11 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
GB2573933B (en) 2017-01-31 2022-07-13 Kimberly Clark Co Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same
US11021529B2 (en) 2017-03-03 2021-06-01 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
JP2020513016A (ja) * 2017-04-06 2020-04-30 アミクローブ，インコーポレイテッド 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用
WO2020162582A1 (en) * 2019-02-08 2020-08-13 Maruho Co., Ltd. Methods of treating non-virally-induced cancers
EP4126064A1 (de) 2020-04-03 2023-02-08 Visterra, Inc. Antikörpermolekül-wirkstoff-konjugate und verwendungen davon
CZ309857B6 (cs) 2022-03-31 2023-12-20 Contipro A.S. Hexapeptid, kompozice zahrnující tento hexapeptid a jejich topické použití

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
JPH0645535B2 (ja) * 1987-05-20 1994-06-15 サンスタ−株式会社 歯槽骨代謝治療用組成物
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US4956184A (en) 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
NZ237202A (en) 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
US5776892A (en) 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
AU1579092A (en) 1991-02-27 1992-10-06 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
US5324716A (en) 1991-06-14 1994-06-28 Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5547939A (en) 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
CA2135194A1 (en) 1992-05-22 1993-12-09 Charles L. Bevins Gastrointestinal defensins, cdna sequences and method for the production and use thereof
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
ES2079994B1 (es) 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
GB9224598D0 (en) * 1992-11-24 1993-01-13 Smithkline Beecham Plc Novel compositions
US5436222A (en) 1993-03-15 1995-07-25 The Research Foundation Of State University Of New York Use of platelet factor 4 to treat inflammatory diseases
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
CA2172245C (en) 1993-09-22 2003-04-08 Jonathan Cohen Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein
EP0754050B1 (de) 1994-01-14 2002-06-26 XOMA Technology Ltd. Anti gram positive bakterielle verfahren und mittel
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5505949A (en) 1994-10-13 1996-04-09 Benitez; Juan E. Topical treatment for acne
US5834430A (en) 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
US6057291A (en) * 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
US5877274A (en) 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
WO1997008199A2 (en) 1995-08-23 1997-03-06 University Of British Columbia Antimicrobial cationic peptides and methods of screening for the same
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
US6248343B1 (en) 1998-01-20 2001-06-19 Ethicon, Inc. Therapeutic antimicrobial compositions
US5997893A (en) 1998-01-20 1999-12-07 Ethicon, Inc. Alcohol based anti-microbial compositions with cosmetic appearance
WO1999043357A1 (en) 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers
US6303575B1 (en) 1998-05-12 2001-10-16 The Regents Of The University Of California Indolicidin analogs and methods of using same
AU4253799A (en) 1998-06-12 2000-01-05 Micrologix Biotech, Inc. Cancer therapy with cationic peptides
US6444645B1 (en) 1998-06-18 2002-09-03 The Regents Of The University Of California Crosslink-stabilized indolicidin analogs
ATE259654T1 (de) 1998-06-26 2004-03-15 Nutricia Nv Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
MXPA01008160A (es) * 1999-02-12 2002-04-24 Procter & Gamble Composiciones desinfectantes de la piel.
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2003500456A (ja) * 1999-06-02 2003-01-07 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 角質細胞増殖因子−２製剤
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof

Also Published As

Publication number Publication date
WO2003015809A3 (en) 2004-03-18
JP5684098B2 (ja) 2015-03-11
WO2003015809A2 (en) 2003-02-27
AU2002324752B2 (en) 2008-07-03
US20150087580A1 (en) 2015-03-26
US8138144B2 (en) 2012-03-20
JP2015028082A (ja) 2015-02-12
US8927487B2 (en) 2015-01-06
US20130296227A1 (en) 2013-11-07
US8466102B2 (en) 2013-06-18
WO2003015809A9 (en) 2004-04-22
JP2012041367A (ja) 2012-03-01
CA2456477A1 (en) 2003-02-27
US20030171281A1 (en) 2003-09-11
US6835536B2 (en) 2004-12-28
US9227999B2 (en) 2016-01-05
US20120202735A1 (en) 2012-08-09
JP2005504769A (ja) 2005-02-17
EP1469876B1 (de) 2011-04-06
JP4932136B2 (ja) 2012-05-16
US20050049182A1 (en) 2005-03-03
CA2456477C (en) 2016-02-16
EP1469876A2 (de) 2004-10-27
ATE504308T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
BR0115531A (pt) Tratamento de mucosites
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2004006858A3 (en) Compounds, compositions, and methods employing same
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
SE9904377D0 (sv) Pharmaceutical combinations
BR9711986A (pt) Compostos farmac-uticos
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
NO20073914L (no) Biologisk aktive peptider
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
AU2003206144A1 (en) Pharmaceutical composition for cancer treatment containing p43 protein and paclitaxel, therapy method using the same and use thereof
WO2003053959A8 (de) Heterocyclylaminocarbo nyluracile
WO2002100342A3 (en) (s, s'), (s, r')-amphetaminil, compositions and uses thereof
WO2002100346A3 (en) (r, r'),(r',s')-amphetaminil, compositions and uses thereof
UA32314A (uk) Спосіб лікування некротичного панкреатиту